, May 27, 2014
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a conference call on June 16
for the media and investment community to provide detailed updates for dulaglutide, its investigational glucagon-like receptor agonist (GLP-1) being studied for the treatment of type 2 diabetes. The call, which is being held in conjunction with the 74th
American Diabetes Association Scientific Sessions, will include updates on Phase III data for dulaglutide, including details on clinical trials vs. liraglutide and insulin glargine.
The conference call will be held from 9:30-10:30 p.m. U.S. Eastern Daylight Time (EDT). Investors, media and the general public can access the live conference call through a link that will be posted on Lilly's website at www.lilly.com. The webcast of the conference call will be available for replay through July 16, 2014.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutionsfrom medicines to support programs and morewe strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.
Candace Johnson (media) (317) 755-9143, firstname.lastname@example.org
Philip Johnson (investors) -- (317) 655-6874, email@example.com
SOURCE Eli Lilly and Company